Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.

Brazil CoronaVac case-control study covid-19 inactivated vaccine test-negative study vaccine waning

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
24 Dec 2021
Historique:
entrez: 6 1 2022
pubmed: 7 1 2022
medline: 7 1 2022
Statut: epublish

Résumé

To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. Test negative case-control study. Community testing for covid-19 in São Paulo state, Brazil. Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days. In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.

Identifiants

pubmed: 34988559
doi: 10.1101/2021.12.23.21268335
pmc: PMC8728874
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI139761
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Declaration of interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nat Commun. 2021 Oct 28;12(1):6220
pubmed: 34711813
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Clin Infect Dis. 2020 Mar 17;70(7):1484-1486
pubmed: 31351439
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Epidemiol Infect. 2019 Nov 27;147:e306
pubmed: 31774051
Science. 2022 Jan 21;375(6578):331-336
pubmed: 34735261
N Engl J Med. 2021 Dec 16;385(25):e90
pubmed: 34551224
BMJ. 2021 Aug 20;374:n2015
pubmed: 34417194
Vaccines (Basel). 2021 Oct 12;9(10):
pubmed: 34696277
Lancet. 2022 Jan 1;399(10319):25-35
pubmed: 34942103
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
Lancet. 2005 Apr 16-22;365(9468):1429-33
pubmed: 15836892
Nature. 2021 Oct;598(7881):398-399
pubmed: 34650240
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275

Auteurs

Matt D T Hitchings (MDT)

Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA.

Otavio T Ranzani (OT)

Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
Pulmonary Division, Heart Institute (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Margaret L Lind (ML)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.

Murilo Dorion (M)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.

Tatiana Lang D'Agostini (TL)

Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.

Regiane Cardoso de Paula (RC)

Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.

Olivia Ferreira Pereira de Paula (OFP)

Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.

Edlaine Faria de Moura Villela (EF)

Disease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.

Mario Sergio Scaramuzzini Torres (MSS)

Municipal Health Secretary of Manaus, Brazil, AM, Brazil.

Silvano Barbosa de Oliveira (SB)

Pan American Health Organization, Brasília, DF, Brazil.
Universidade de Brasília, Brasília, DF, Brazil.

Wade Schulz (W)

Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.

Maria Almiron (M)

Pan American Health Organization, Brasília, DF, Brazil.

Rodrigo Said (R)

Pan American Health Organization, Brasília, DF, Brazil.

Roberto Dias de Oliveira (RD)

State University of Mato Grosso do Sul - UEMS, Dourados, MS, Brazil.

Patricia Vieira da Silva (PV)

Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.

Wildo Navegantes de Araújo (WN)

Pan American Health Organization, Brasília, DF, Brazil.
Universidade de Brasília, Brasília, DF, Brazil.
National Institute for Science and Technology for Health Technology Assessment, Porto Alegre, RS, Brazil.

Jean Carlo Gorinchteyn (JC)

Health Secretariat of the State of São Paulo, São Paulo, Brazil.

Natalie E Dean (NE)

Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University.

Jason R Andrews (JR)

Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.

Derek A T Cummings (DAT)

Department of Biology, University of Florida, Gainesville, FL, USA.
Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.

Albert I Ko (AI)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brazil.

Julio Croda (J)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, MS, Brazil.

Classifications MeSH